Blood Res.  2022 Jun;57(2):95-100. 10.5045/br.2022.2021173.

Chronic myeloid leukemia: a type of MPN

• Samad MA
• Mahboob E
• Mansoor H

• KMID: 2530872
• DOI: http://doi.org/10.5045/br.2022.2021173

Abstract

This review article classifies chronic myeloid leukemia (CML) based on cytogenetic analyses and different mutations detected in CML patients. The use of advanced technologies, such as karyotyping, fluorescent in situ hybridization, and comparative genomic hybridization, has allowed us to study CML in detail and observe the different biochemical changes that occur in different CML types. This review also highlights the different types of receptor and signaling pathway mutations that occur in CML.

Keyword

Chronic myeloid leukemia; Cytogenetics; Philadelphia chromosome; Myeloproliferative neoplasms

Figure

• 

  Fig. 1 Translocation of the break-point cluster region (BCR) gene.

• 

  Fig. 2 Gene mutations detected in patients with chronic myelomono-cytic leukemia (CMML).

Reference

1. Besa EC, Grethlein SJ. 2021. Chronic myelogenous leukemia (CML): practice essentials, background, pathophysiology. Medscape;New York, NY: at https://medicine.medscape.com/article/199425-overview. Accessed September 11, 2021.

2. Shtivelman E, Lifshitz B, Gale RP, Canaani E. 1985; Fused transcript of ABL and BCR genes in chronic myelogenous leukaemia. Nature. 315:550–4. DOI: 10.1038/315550a0. PMID: 2989692.

3. Swerdlow SH, Campo E, Harris NL, et al. 2008. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. IARC Press;Lyon, France: DOI: 10.1038/315550a0.

4. Hagemeijer A. 1987; Chromosome abnormalities in CML. Baillieres Clin Haematol. 1:963–81. DOI: 10.1016/S0950-3536(87)80034-3. PMID: 3332858.

5. Score J, Calasanz MJ, Ottman O, et al. 2010; Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation. Leukemia. 24:1742–50. DOI: 10.1038/leu.2010.174. PMID: 20703256.

6. Kang ZJ, Liu YF, Xu LZ, et al. 2016; The Philadelphia chromosome in leukemogenesis. Chin J Cancer. 35:48. DOI: 10.1186/s40880-016-0108-0. PMID: 27233483. PMCID: PMC4896164.

7. Pane F, Frigeri F, Sindona M, et al. 1996; Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 88:2410–4. DOI: 10.1182/blood.V88.7.2410.bloodjournal8872410. PMID: 8839830.

8. Kantarjian HM, Smith TL, McCredie KB, et al. 1985; Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood. 66:1326–35. DOI: 10.1182/blood.V66.6.1326.1326. PMID: 3864497.

9. Bartram CR, de Klein A, Hagemeijer A, et al. 1983; Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 306:77–80. DOI: 10.1038/306277a0. PMID: 6580527.

10. Kantarjian HM, Keating MJ, Walters RS, et al. 1986; Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer. 58:2023–30. DOI: 10.1002/1097-0142(19861101)58:9<2023::AID-CNCR2820580912>3.0.CO;2-H. PMID: 3463397.

11. Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C. 2008; The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol. 87:1–10. DOI: 10.1007/s00277-007-0403-6. PMID: 17938925. PMCID: PMC2082654.

12. Kralovics R, Passamonti F, Buser AS, et al. 2005; A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 352:1779–90. DOI: 10.1056/NEJMoa051113. PMID: 15858187.

13. Tefferi A, Lasho TL, Gilliland G. 2005; JAK2 mutations in myelo-proliferative disorders. N Engl J Med. 353:1416–7. author reply 1416–7. DOI: 10.1056/NEJMc051878. PMID: 16192494.

14. Tefferi A, Thiele J, Orazi A, et al. 2007; Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 110:1092–7. DOI: 10.1182/blood-2007-04-083501. PMID: 17488875.

15. Böhm J, Kock S, Schaefer HE, Fisch P. 2003; Evidence of clonality in chronic neutrophilic leukaemia. J Clin Pathol. 56:292–5. DOI: 10.1136/jcp.56.4.292. PMID: 12663642. PMCID: PMC1769920.

16. Jaffe ES, Harris NL, Stein H, Vardiman JW. 2001. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. WHO classification of tumours. 3rd ed. IARC Press;Lyon, France: DOI: 10.3410/f.1087119.540101.

17. Saglio G, Guerrasio A, Rosso C, et al. 1990; New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 76:1819–24. DOI: 10.1182/blood.V76.9.1819.1819. PMID: 2224129.

18. You W, Weisbrot IM. 1979; Chronic neutrophilic leukemia. Report of two cases and review of the literature. Am J Clin Pathol. 2:233–42. DOI: 10.1093/ajcp/72.2.233. PMID: 289288.

19. Verstovsek S, Lin H, Kantarjian H, et al. 2002; Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer. 94:2416–25. DOI: 10.1002/cncr.10490. PMID: 12015767.

20. Maxson JE, Tyner JW. 2017; Genomics of chronic neutrophilic leukemia. Blood. 129:715–22. DOI: 10.1182/blood-2016-10-695981. PMID: 28028025. PMCID: PMC5301820.

21. Vandenberghe P, Wlodarska I, Michaux L, et al. 2004; Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia. 18:734–42. DOI: 10.1038/sj.leu.2403313. PMID: 14973504.

22. Gotlib J. 2017; World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 92:1243–59. DOI: 10.1002/ajh.24880. PMID: 29044676.

23. Bain BJ, Gilliland DG, Horny HP, Vardiman JW. 2008; Chronic eosinophilic leukemia, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al, eds.WHO classification of tumours of haematopoietic and lymphoid tissues. WHO classification of tumours. 4th ed. Lyon, France:. IARC Press,. 51–3.

24. Murray NP. 2015; Chronic eosinophilic leukemia: a mini-review. J Hematol Blood Transfus Disord. 2:100004. DOI: 10.24966/HBTD-2999/100004.

25. Pardanani A, Brockman SR, Paternoster SF, et al. 2004; FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 104:3038–45. DOI: 10.1182/blood-2004-03-0787. PMID: 15284118.

26. Metzgeroth G, Erben P, Martin H, et al. 2012; Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia. 26:162–4. DOI: 10.1038/leu.2011.181. PMID: 21818111.

27. Oliver JW, Deol I, Morgan DL, Tonk VS. 1998; Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review, and report of a case with a unique chromosomal abnormality. Cancer Genet Cytogenet. 107:11–7. DOI: 10.1016/S0165-4608(98)00099-5. PMID: 9844604.

28. Ma SK, Kwong YL, Shek TW, et al. 1999; The role of trisomy 8 in the pathogenesis of chronic eosinophilic leukemia. Hum Pathol. 30:864–8. DOI: 10.1016/S0046-8177(99)90149-1. PMID: 10414507.

29. Saitoh T, Saiki M, Inoue M, et al. 2002; CD25 positive chronic eosinophilic leukemia with myelofibrosis. Rinsho Ketsueki. 3:918–23. PMID: 12462027.

30. Lepretre S, Jardin F, Buchonnet G, et al. 2002; Eosinophilic leukemia associated with t(2;5)(p23;q31). Cancer Genet Cytogenet. 33:164–7. DOI: 10.1016/S0165-4608(01)00590-8. PMID: 11943346.

31. Granjo E, Lima M, Lopes JM, et al. 2002; Chronic eosinophilic leukaemia presenting with erythroderma, mild eosinophilia and hyper-IgE: clinical, immunological and cytogenetic features and therapeutic approach. A case report. Acta Haematol. 107:108–12. DOI: 10.1159/000046640. PMID: 11919392.

32. Patnaik MM, Padron E, LaBorde RR, et al. 2013; Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 27:1504–10. DOI: 10.1038/leu.2013.88. PMID: 23531518.

33. Arber DA, Orazi A, Hasserjian R, et al. 2016; The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–405. DOI: 10.1182/blood-2016-03-643544. PMID: 27069254.

34. Harris NL, Jaffe ES, Diebold J, et al. 1999; World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 17:3835–49. DOI: 10.1200/JCO.1999.17.12.3835. PMID: 10577857.

35. Vardiman JW, Pierre R, Bain B, et al. 2001; WHO histological classification of myelodysplastic/myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France:. IARC Press,. 47–59.

36. Patnaik MM, Parikh SA, Hanson CA, Tefferi A. 2014; Chronic myelomonocytic leukaemia: a concise clinical and patho-physiological review. Br J Haematol. 165:273–86. DOI: 10.1111/bjh.12756. PMID: 24467717.

37. Jankowska AM, Makishima H, Tiu RV, et al. 2011; Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 118:3932–41. DOI: 10.1182/blood-2010-10-311019. PMID: 21828135. PMCID: PMC3193268.

38. Smith AE, Mohamedali AM, Kulasekararaj A, et al. 2010; Next- eneration sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood. 116:923–32. DOI: 10.1182/blood-2010-03-274704. PMID: 20693430.

39. Itzykson R, Kosmider O, Renneville A, et al. 2013; Clonal architecture of chronic myelomonocytic leukemias. Blood. 121:2186–98. DOI: 10.1182/blood-2012-06-440347. PMID: 23319568.

40. Niemeyer CM, Arico M, Basso G, et al. 1997; Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood. 89:3534–43. PMID: 9160658.

41. Aricò M, Biondi A, Pui CH. 1997; Juvenile myelomonocytic leukemia. Blood. 90:479–88. DOI: 10.1182/blood.V90.2.479. PMID: 9226148. PMCID: PMC9120833.

42. Orazi A, Germing U. 2008; The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia. 22:1308–19. DOI: 10.1038/leu.2008.119. PMID: 18480833.

43. Emanuel PD. 1999; Myelodysplasia and myeloproliferative disorders in childhood: an update. Br J Haematol. 105:852–63. DOI: 10.1111/j.1365-2141.1999.01435.x. PMID: 10554793.

44. Hasle H, Niemeyer CM, Chessells JM, et al. 2003; A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 17:277–82. DOI: 10.1038/sj.leu.2402765. PMID: 12592323.

45. Niemeyer CM, Locatelli F. 2006; Chronic myeloproliferative disorders. In: Pui CH. Childhood leukemias. New York, NY:. Cambridge University Press,. 571–98. DOI: 10.1017/CBO9780511471001.023. PMID: 17140547.

46. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. 1991; Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 77:925–9. DOI: 10.1182/blood.V77.5.925.925. PMID: 1704804.

47. Pinkel D. 1998; Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood. 91:365–7. DOI: 10.1182/blood.V91.1.365. PMID: 9414312.

48. Tartaglia M, Niemeyer CM, Fragale A, et al. 2003; Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 4:148–50. DOI: 10.1038/ng1156. PMID: 12717436.

49. Caye A, Strullu M, Guidez F, et al. 2015; Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nat Genet. 47:1334–40. DOI: 10.1038/ng.3420. PMID: 26457648.

50. Stieglitz E, Taylor-Weiner AN, Chang TY, et al. 2015; The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 47:1326–33. DOI: 10.1038/ng.3400. PMID: 26457647. PMCID: PMC4626387.

51. Sakaguchi H, Okuno Y, Muramatsu H, et al. 2013; Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet. 45:937–41. DOI: 10.1038/ng.2698. PMID: 23832011.

52. Flotho C, Kratz CP, Bergsträsser E, et al. 2008; Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood. 111:966–7. DOI: 10.1182/blood-2007-09-111831. PMID: 18182584.

53. Matsuda K, Shimada A, Yoshida N, et al. 2007; Spontaneous improve-ment of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood. 109:5477–80. DOI: 10.1182/blood-2006-09-046649. PMID: 17332249.

54. Locatelli F, Niemeyer CM. 2015; How I treat juvenile myelomonocytic leukemia. Blood. 125:1083–90. DOI: 10.1182/blood-2014-08-550483. PMID: 25564399.

55. Tefferi A. 2016; Primary myelofibrosis: 2017 update on diagnosis, risk- tratification, and management. Am J Hematol. 91:1262–71. DOI: 10.1002/ajh.24592. PMID: 27870387.